Cagrilintide vs Retatrutide vs Tirzepatide: How They Compare

The short answer: cagrilintide, retatrutide, and tirzepatide are all injectable drugs built on gut-hormone signaling, but only tirzepatide is FDA-approved for human use in the United States. Tirzepatide is a dual GLP-1 and GIP agonist sold as Mounjaro and Zepbound, cagrilintide is an amylin analog studied mostly alongside semaglutide, and retatrutide is an investigational triple agonist. Retatrutide has posted the largest average weight loss in trials so far, yet it remains years away from pharmacy shelves.

What Each Drug Actually Is

Cagrilintide, retatrutide, and tirzepatide come from two competing companies and three different receptor strategies. That difference explains almost everything about how they perform and who can legally use them today.

• Tirzepatide — developed by Eli Lilly and approved by the FDA as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). It is given as a once-weekly subcutaneous injection.
• Cagrilintide — a long-acting amylin analog from Novo Nordisk, tested as a standalone weekly injection and in combination with semaglutide under the name CagriSema.
• Retatrutide — also from Eli Lilly, a single molecule that activates three receptors at once. It is still investigational, with phase 3 trials ongoing.

How Their Mechanisms Differ

GLP-1 receptor activation slows stomach emptying and increases feelings of fullness, and it is the backbone of nearly every modern weight-loss drug. GIP adds a second satiety signal, while glucagon receptor activation appears to raise energy expenditure — a different lever than appetite alone.

Cagrilintide works through amylin receptors, not GLP-1 receptors, which is why it is usually paired with semaglutide instead of being judged on its own. Amylin and GLP-1 both slow digestion, but they act on separate brain circuits.

A useful rule applies here just as it does to tirzepatide vs semaglutide which is better for weight loss — hitting more receptors is not automatically the same as being the better choice for a specific patient.

Weight Loss Results: How the Numbers Compare

Cross-trial comparisons are imperfect because the studies enrolled different populations and ran for different lengths of time. Even so, the headline results show a clear ranking in average weight lost.

Retatrutide produced the largest average weight reduction of the three in its phase 2 trial, with many participants losing more than 25% of their body weight. Tirzepatide's advantage is that its results are already reproducible in routine clinical practice, not only inside a controlled study.

Cagrilintide on its own looks modest next to the others, which is exactly why Novo Nordisk is pursuing CagriSema rather than cagrilintide monotherapy. CagriSema's phase 3 numbers landed close to tirzepatide's, though slightly below some analyst expectations.

Availability and Legal Status in the US

Tirzepatide is the only one of the three you can get with a prescription today. It is dispensed through retail and mail-order pharmacies under two brand names.

Cagrilintide and retatrutide are available in the United States only through clinical trials. Products labeled as cagrilintide or retatrutide for sale online are sold as research chemicals, are not FDA-approved, and carry no guarantee of purity, dose accuracy, or sterility.

Compounded tirzepatide became a gray area once the FDA declared the shortage resolved, and most large compounding pharmacies were told to stop making copies of the brand product. People comparing lipo-c vs tirzepatide should know that lipotropic injections and FDA-approved incretin drugs are not interchangeable — one is a vitamin-and-amino-acid blend with limited weight-loss evidence, and the other has large randomized trials behind it.

Side Effects and Safety Considerations

The three drugs share a similar gastrointestinal profile: nausea, vomiting, diarrhea, constipation, and abdominal discomfort, especially during dose escalation. Injection site reactions and fatigue are also common.

More serious but less frequent risks reported with incretin-based drugs include gallbladder disease, pancreatitis, and rapid loss of lean muscle mass. People with a personal or family history of medullary thyroid cancer or MEN2 syndrome are advised to avoid GLP-1-based products.

Because cagrilintide and retatrutide are investigational, their long-term safety profile is still being characterized. There is no published human data on aod 9604 and tirzepatide together side effects, so any claim that stacking them is safe or effective is speculation rather than evidence.

Interest in combining compounds keeps growing — searches for aod 9604 and retatrutide are a good example — but no trial has tested these pairings, and unregulated peptides add risk without adding proven benefit. People exploring peptides often ask about sermorelin vs aod 9604 as well, though those compounds target growth hormone and fat metabolism rather than appetite.

Which One Makes Sense for You?

If you need treatment now, tirzepatide is the realistic option among these three because it has an approved indication, defined dosing, and years of accumulated trial data behind it.

If you qualify for a clinical trial of retatrutide or CagriSema, that is currently the only legitimate route to those drugs. Waiting lists, travel requirements, and eligibility criteria are real obstacles, and trial participation is not the same as routine care.

Dosing decisions, titration speed, and monitoring belong with a licensed healthcare professional who knows your history. Self-sourcing any of these compounds online is the single biggest avoidable risk.

Bottom Line

Retatrutide has shown the strongest average weight loss in trials, tirzepatide is the only FDA-approved option of the three, and cagrilintide's future depends largely on the CagriSema combination. None of them is a cure, and all of them require medical supervision and long-term lifestyle support to work well.